Acadia Healthcare Company, Inc. SEC filings document the company's behavioral healthcare operations, public-company governance and capital structure. Its disclosures describe subsidiaries that own, operate or manage acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers, residential treatment centers and outpatient behavioral healthcare facilities in the U.S. and Puerto Rico.
Acadia's filings include Form 8-K reports on operating and financial results, Regulation FD materials, executive and director changes, separation and compensation arrangements, and shareholder voting outcomes. Proxy materials cover board elections, executive compensation, incentive compensation plans and annual-meeting proposals, while registered-security disclosures identify ACHC common stock on the NASDAQ Global Select Market.
Acadia Healthcare investor group led by Khrom Investments reports beneficial ownership of 5,201,533 shares, representing 5.66% of outstanding common stock as of March 31, 2026. The filing states Khrom Investments directly holds 5,194,625 shares and Eric Khrom directly holds 6,928 shares.
The disclosure explains voting and dispositive power: Khrom Capital exercises shared voting and dispositive power over the shares held by Khrom Investments, and Mr. Khrom may be deemed to share those powers through affiliated entities; Mr. Khrom disclaims beneficial ownership except to the extent of any pecuniary interest.
Acadia Healthcare Company, Inc. Schedule 13G/A reports that Wellington Management entities together beneficially own 9,072,942 shares of Acadia common stock, representing 9.86% of the class. The filing lists shared voting and dispositive powers across related Wellington entities and identifies underlying adviser-client record ownership.
Acadia Healthcare Company, Inc. disclosed the initial equity holdings of Interim CFO David M. Duckworth in a Form 3 filing. The report shows he holds 750 shares of Common Stock directly, providing a baseline of his ownership but not recording any recent purchases or sales.
The Goldman Sachs Group, Inc. and Goldman Sachs & Co. LLC filed an amendment to a Schedule 13G reporting shared voting and shared dispositive power in ACADIA HEALTHCARE COMPANY, INC. The cover data shows shared voting power of 1,453,488.72 shares, shared dispositive power of 1,454,430.72 shares and a reported total of 1,464,125.72 shares representing 1.6% of the class as of 03/31/2026. The filing is a joint filing under a Joint Filing Agreement signed by Sam Prashanth on 04/24/2026.
Fucci Michael reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Michael Fucci received a grant of 6,331 shares of common stock as compensation. The shares were awarded at no cash cost to him and will vest over a three-year period in equal yearly installments beginning on May 6, 2027. After this grant, he directly holds a total of 28,152 shares of Acadia Healthcare common stock. This is a routine equity award rather than an open-market purchase or sale.
Acadia Healthcare Company, Inc. director Ralph David Kelly received a grant of 6,331 shares of Common Stock on May 6, 2026. The award carries no cash purchase price and represents a grant, award, or other acquisition of shares. These shares will vest over three years in equal yearly installments beginning May 6, 2027. Following this grant, Kelly directly holds 26,358 shares of Acadia Healthcare common stock.
Gregg Vicky B reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Vicky B. Gregg reported receiving a stock award of 6,331 shares of common stock on May 6, 2026. The grant was at no cash cost per share and increased her direct holdings to 42,628 shares after the transaction. According to the filing, these awarded shares will vest over three years in equal yearly installments beginning May 6, 2027, meaning portions of the grant become available gradually rather than all at once.
Bernhard Jason reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director Jason Bernhard reported two stock awards of common stock on May 6, 2026. The filings show grants of 5,124 shares and 6,331 shares at a stated price of $0.00 per share, indicating compensation awards rather than open-market purchases.
Footnotes explain that the shares will vest over a three-year period in equal yearly installments beginning May 6, 2027, and that one award reflects Mr. Bernhard’s election to receive his 2026 annual cash retainer as a director in shares of common stock.
GRIECO WILLIAM reported acquisition or exercise transactions in this Form 4 filing.
Acadia Healthcare Company, Inc. director William Grieco received an equity grant of 6,331 shares of Common Stock as compensation. The shares were awarded at no cash cost to him and increase his directly held stake to 96,212 shares.
The granted shares will vest over three years in equal yearly installments beginning on May 6, 2027, meaning he earns the shares gradually over time as service continues on the board.